Klin Farmakol Farm. 2010;24(4):184-186

Options fluorochinolones in current clinical practice

Vojtěch Hanulík, Miroslava Htoutou Sedláková, Jana Petrželová, Milan Kolář
Ústav mikrobiologie LF UP a FN Olomouc

Fluoroquinolones are purely synthetic agents with antibacterial effects. For their excellent properties and a broad spectrum of activity,

they are well established in the treatment of many bacterial diseases. Fluoroquinolones are commonly used in both human and veterinary

medicine. However, their application is associated with potential development and spread of bacterial resistance, impairing the

activity of these excellent agents.

Keywords: resistance, mechanism, indication, moxifloxacine

Published: December 31, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hanulík V, Htoutou Sedláková M, Petrželová J, Kolář M. Options fluorochinolones in current clinical practice. Klin Farmakol Farm. 2010;24(4):184-186.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 2000; 16: 5-15. Go to original source... Go to PubMed...
    2. Wolfson JS, Hooper DC. The fluoroquinolones: Structures, mechanisms of action and resistence, and spectra of aktivity in vitro. Antimicrob Agents Chemother 1985; 28: 581-586. Go to original source... Go to PubMed...
    3. Drlica K. Mechanism of fluoroquinolone action. Curr Opin Microbiol 1999; 2: 504-508. Go to original source... Go to PubMed...
    4. Drlica K. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997; 61: 377-392. Go to original source... Go to PubMed...
    5. Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updat 1999; 2: 38-55. Go to original source... Go to PubMed...
    6. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2000; 7: 337-441. Go to original source... Go to PubMed...
    7. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25: 1196-1204. Go to original source... Go to PubMed...
    8. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use-safety report. Pediatr Infect Dis 1997; 16: 127-129. Go to original source... Go to PubMed...
    9. Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents 2009; 33: 194-200. Go to original source... Go to PubMed...
    10. Owens RC, Ambrose PG. Antimicrobial safety: Focus on fluoroquinolones. Clin Infect Dis 2005; 41: 141-157. Go to original source... Go to PubMed...
    11. Ball P, Quinolone generations: natural history or natural selection? J Antibicrob Chemother 2000; 46: 17-24. Go to original source... Go to PubMed...
    12. Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chemother 2003; 51: 1-11. Go to original source... Go to PubMed...
    13. Subkomise pro antibiotickou politiku a Komise pro lékovou politiku a kategorizaci léčiv ČLS JEP. Konsensus používání antibiotik III. Chinolony. Farmakoterapeutické informace 2006; 16: 1-4.
    14. Subkomise pro antibiotickou politiku a Komise pro lékovou politiku a kategorizaci léčiv ČLS JEP. Konsensus používání antibiotik III. Chinolony. Farmakoterapeutické informace 2007; 1: 1-2.
    15. Jindrák V, Urbášková P, Nyč O. Fluorochinolony - kriticky ohrožená skupina antibiotik. Practicus 2007; 6: 6-11.
    16. EARSS. http://www.rivm.nl/earss.
    17. Ferech M, Soenen S, Malhotra-Kumar S, et al. European surveillance of antimicrobial consumption outpatient quinolone use in Europe. J Antimicrob Chemother 2006; 58: 423-427. Go to original source... Go to PubMed...
    18. Malhotra-Kumar S, Van Heirstraeten L, Lammens Ch, Chapelle S, Goossens H. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin. J Antimicrob Chemother 2009; 63: 886-894. Go to original source... Go to PubMed...
    19. Kolář M. Antimikrobní léčba komunách bakteriálních infekcí - je nutná změna? Medicína pro praxi 2009; 10: 57-62.
    20. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patiens with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24: 111-118. Go to original source... Go to PubMed...
    21. Cattaneo C, Quaresmini G, Casari S, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patiens with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008; 61: 721-728. Go to original source... Go to PubMed...
    22. Thorsteinsdottir TR, Haraldsson G, Fridriksdottir V, Gristinsson KG, Gunnarsson E. Broiler chickens as source of human fluoroquinolone-resistant Escerichia coli, Iceland. Emerg Infect Dis 2010; 16: 133-135. Go to original source... Go to PubMed...
    23. Kolář M, Bardoň J, Sauer P, et al. Fluoroquinolone-resistant Escherichia coli and Proteus mirabilis in poultry of middle Moravia, Czech Republic. Acta Vet Brno 2005; 74: 249-253. Go to original source...
    24. EPIDAT. http://www.szu.cz/publikace/data/vybrane-infekcni-nemoci-v-cr-v-letech-1998-2007-relativne.
    25. Bardoň J, Kolář M, Karpíšková R, Hricová K. Prevalence of thermotolerant Campylobacter spp. in broilers at retail in the Czech Republic and their antibiotic resistance. Food Control 2010; in press. Go to original source... Go to PubMed...
    26. Monografie - Kolář M, Látal T, Čermák P. Klinicko-mikrobiologické podklady racionální antibiotické léčby. Praha: Trios, s.r.o., 2002: 110.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.